Milliman
GLP-1 Drug Spending Surge Forces Payers—Including Medicaid—to Rethink Coverage Strategy
Milliman examines the rapid growth of GLP-1 medication spending (from $13.7B to $71.7B in five years) and lays out considerations for payers on benefit design, utilization management, and total cost of care rather than just unit price. While the analysis spans commercial, Medicare, and Medicaid markets broadly, it has direct relevance for Medicaid MCOs and state programs grappling with obesity drug coverage mandates and cost containment, and links to related Milliman work specifically on Medicaid anti-obesity medication coverage.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.